Review
Urology & Nephrology
Morgan Roupret, Thomas Seisen, Alison J. Birtle, Otakar Capoun, Jose L. Dominguez-Escrig, Irene Gurses Andersson, Eva M. Comperat, Fredrik Liedberg, Paramananthan Mariappan, A. Hugh Mostafid, Benjamin Pradere, Bas W. G. van Rhijn, Shahrokh F. Shariat, Bhavan P. Rai, Francesco Soria, Viktor Soukup, Robbert G. Wood, Evanguelos N. Xylinas, Alexandra Masson-Lecomte, Paolo Gontero
Summary: The European Association of Urology has updated the guidelines for the management of upper urinary tract urothelial carcinoma. The recommendations are based on a systematic review of the literature and assessed by a panel of experts. However, there is still insufficient high-level evidence in many areas to provide strong recommendations.
Review
Urology & Nephrology
Morgan Roupret, Marko Babjuk, Maximilian Burger, Otakar Capoun, Daniel Cohen, Eva M. Comperat, Nigel C. Cowan, Jose L. Dominguez-Escrig, Paolo Gontero, A. Hugh Mostafid, Joan Palou, Benoit Peyronnet, Thomas Seisen, Viktor Soukup, Richard J. Sylvester, Bas W. G. van Rhijn, Richard Zigeuner, Shahrokh F. Shariat
Summary: The updated EAU guidelines on UTUC aim to assist clinicians in evidence-based management, providing recommendations on diagnosis, risk stratification, radical and conservative treatment, and prognostic factors. Due to the rarity of UTUC, there is insufficient data to provide strong recommendations. Recommendations are based on the 2017 TNM classification and emphasize individualized treatment based on proposed risk stratification.
Review
Urology & Nephrology
J. Alfred Witjes, Harman Max Bruins, Richard Cathomas, Eva M. Comperat, Nigel C. Cowan, Georgios Gakis, Virginia Hernandez, Estefania Linares Espinos, Anja Lorch, Yann Neuzillet, Mathieu Rouanne, George N. Thalmann, Erik Veskimae, Maria J. Ribal, Antoine G. van der Heijden
Summary: This article presents the updated European Association of Urology guidelines for muscle-invasive and metastatic bladder cancer, providing practical evidence-based recommendations and consensus statements on clinical management. The guidelines cover a broad scope and incorporate the latest research findings and results from consensus meetings.
Review
Urology & Nephrology
Marko Babjuk, Maximilian Burger, Otakar Capoun, Daniel Cohen, Eva M. Comperat, Jose L. Dominguez Escrig, Paolo Gontero, Fredrik Liedberg, Alexandra Masson-Lecomte, A. Hugh Mostafid, Joan Palou, Bas W. G. van Rhijn, Morgan Roupret, Shahrokh F. Shariat, Thomas Seisen, Viktor Soukup, Richard J. Sylvester
Summary: The updated EAU guidelines provide new information on the diagnosis and treatment of NMIBC for clinical practice. Individual risk assessment is crucial in determining the appropriate treatment for patients with different risk levels. Surgical intervention, including radical cystectomy, may be necessary for cases unresponsive to BCG treatment or with high risk of progression.
Review
Urology & Nephrology
Borje Ljungberg, Laurence Albiges, Yasmin Abu-Ghanem, Jens Bedke, Umberto Capitanio, Saeed Dabestani, Sergio Fernandez-Pello, Rachel H. Giles, Fabian Hofmann, Milan Hora, Tobias Klatte, Teele Kuusk, Thomas B. Lam, Lorenzo Marconi, Thomas Powles, Rana Tahbaz, Alessandro Volpe, Axel Bex
Summary: The European Association of Urology has prepared evidence-based guidelines for the management of RCC, which were updated in 2022 using a standardized methodology. The guidelines provide transparent and reliable evidence for the management of RCC, based on a thorough literature assessment and clinical practice recommendations.
Article
Oncology
Nicholas H. Chakiryan, Da David Jiang, Kyle A. Gillis, Elizabeth Green, Ali Hajiran, Lee Hugar, Logan Zemp, Jingsong Zhang, Rohit Jain, Jad Chahoud, Roger Li, Wade Sexton, Brandon J. Manley, Scott M. Gilbert
Summary: This retrospective study compared the overall survival (OS) between first-line immunotherapy and chemotherapy in patients with metastatic bladder urothelial carcinoma. The findings suggest that there is no significant difference in OS between the two treatments.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Article
Oncology
Jian-zhou Cao, Wei Wu, Jin-feng Pan, Hong-wei Wang, Jun-hui Jiang, Qi Ma
Summary: This case report highlights the use of anlotinib combined with sintilimab in the treatment of metastatic urothelial bladder carcinoma (mUBC) patients with FGFR3 mutations, showing partial response and stable disease for over 11 months. The combination therapy was found to be safe and effective in improving the patient's quality of life.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Andrew B. Katims, Peter A. Reisz, Lucas Nogueira, Hong Truong, Andrew T. Lenis, Eugene J. Pietzak, Kwanghee Kim, Jonathan A. Coleman
Summary: Urothelial carcinoma is a malignancy with poor prognosis. The standard treatment is chemotherapy followed by immunotherapy, but the survival outcomes are still unsatisfactory. New targeted therapies have been identified and shown efficacy as second-line treatment, which can be extended to other treatment categories.
Article
Biochemistry & Molecular Biology
Joohyun Hong, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park
Summary: The treatment of metastatic urothelial carcinoma after failure with platinum-based chemotherapy and immune checkpoint inhibitors remains controversial. This study found that participation in clinical trials and having a good performance status are associated with benefits from subsequent therapy for pretreated mUC.
Article
Pharmacology & Pharmacy
Ruiyan Xie, Ming Xie, Litong Zhu, Joanne W. Y. Chiu, Wayne Lam, Desmond Y. H. Yap
Summary: The role of pyroptosis and its effects on tumor-infiltrating cells (TICs) in bladder urothelial carcinoma (BLCA) remains unclear. This study investigated the associations between pyroptosis-related genes (PRGs), TICs, and clinical outcomes of BLCA patients. The findings suggest that PRGs, especially CASP8, show strong associations with patient outcomes and TICs in BLCA.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Alexander Chehrazi-Raffle, Luis Meza, Marice Alcantara, Nazli Dizman, Paulo Bergerot, Nicholas Salgia, JoAnn Hsu, Nora Ruel, Sabrina Salgia, Jasnoor Malhotra, Ewa Karczewska, Marcin Kortylewski, Sumanta Pal
Summary: This study found that specific plasma cytokines were associated with clinical benefit in patients with renal cell carcinoma receiving VEGF-TKI or ICI therapy. These findings support further investigation into plasma cytokines as potential biomarkers for renal cell carcinoma.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Urology & Nephrology
Salvador Arlandis, Kari Bo, Hanny Cobussen-Boekhorst, Elisabetta Costantini, Monica de Heide, Fawzy Farag, Jan Groen, Markos Karavitakis, Marie Carmela Lapitan, Margarida Manso, Serenella Monagas Arteaga, Arjun K. Nambiar, Aisling Nic An Riogh, Eabhann O'Connor, Muhammad Imran Omar, Benoit Peyronnet, Veronique Phe, Vasileios Sakalis, Neha Sihra, Lazaros Tzelves, Mary-Lynne van Poelgeest-Pomfret, Tine W. L. van den Bos, Huub van der Vaart, Christopher K. Harding
Summary: This study summarizes the guidelines from the European Association of Urology on the management of non-neurogenic female lower urinary tract symptoms, including underactive bladder, bladder outlet obstruction, and nocturia.
Article
Urology & Nephrology
Arlene O. Siefker-Radtke, Daniel C. Cho, Adi Diab, Mario Sznol, Mehmet A. Bilen, Arjun Balar, Giovanni Grignani, Erika Puente, Lily Tang, David Chien, Ute Hoch, Arkopal Choudhury, Danni Yu, Sue L. Currie, Mary A. Tagliaferri, Jonathan Zalevsky, Michael E. Hurwitz, Nizar M. Tannir
Summary: The study evaluated the effectiveness of the immunostimulatory cytokine prodrug BEMPEG plus nivolumab as a first-line treatment for advanced/metastatic urothelial carcinoma patients, showing that the combination was well-tolerated and demonstrated good antitumor activity.
Review
Urology & Nephrology
Mauro Gacci, Vasileios Sakalis, Markos Karavitakis, Jean-Nicolas Cornu, Christian Gratzke, Thomas R. W. Herrmann, Iason Kyriazis, Sachin Malde, Charalampos Mamoulakis, Malte Rieken, Natasha Schouten, Emma J. Smith, Mark J. Speakman, Kari A. O. Tikkinen, Stavros Gravas
Summary: This 2022 European Association of Urology guideline summary provides updated information on the definition, pathophysiology, diagnosis, and treatment of male UI, and introduces treatment methods for different types of UI.
Article
Oncology
Kazutaka Nakamura, Yudai Ishiyama, Yuki Nemoto, Hiroki Ishihara, Hidekazu Tachibana, Hironori Fukuda, Hiroaki Shinmura, Yasunobu Hashimoto, Kazuhiko Yoshida, Junpei Iizuka, Hideki Ishida, Tsunenori Kondo, Toshio Takagi
Summary: The study finds that lung immune prognostic index score (LIPI) can serve as a significant prognostic biomarker for metastatic urothelial carcinoma (mUC) treated with pembrolizumab. LIPI is significantly associated with progression-free survival (PFS), overall survival (OS), and disease control rates (DCRs) in patients.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Urology & Nephrology
J. Alfred Witjes, Harman Max Bruins, Richard Cathomas, Eva M. Comperat, Nigel C. Cowan, Georgios Gakis, Virginia Hernandez, Estefania Linares Espinos, Anja Lorch, Yann Neuzillet, Mathieu Rouanne, George N. Thalmann, Erik Veskimae, Maria J. Ribal, Antoine G. van der Heijden
Summary: This article presents the updated European Association of Urology guidelines for muscle-invasive and metastatic bladder cancer, providing practical evidence-based recommendations and consensus statements on clinical management. The guidelines cover a broad scope and incorporate the latest research findings and results from consensus meetings.
Article
Medicine, Research & Experimental
Agathe Dubuisson, Jean-Eudes Fahrner, Anne-Gaelle Goubet, Safae Terrisse, Nicolas Voisin, Charles Bayard, Sebastien Lofek, Damien Drubay, Delphine Bredel, Severine Mouraud, Sandrine Susini, Alexandria Cogdill, Lucas Rebuffet, Elise Ballot, Nicolas Jacquelot, Vincent Thomas de Montpreville, Odile Casiraghi, Camelia Radulescu, Sophie Ferlicot, David J. Figueroa, Sapna Yadavilli, Jeremy D. Waight, Marc Ballas, Axel Hoos, Thomas Condamine, Bastien Parier, Christophe Gaudillat, Bertrand Routy, Francois Ghiringhelli, Lisa Derosa, Ingrid Breuskin, Mathieu Rouanne, Fabrice Andre, Cedric Lebacle, Herve Baumert, Marie Wislez, Elie Fadel, Isabelle Cremer, Laurence Albiges, Birgit Geoerger, Jean-Yves Scoazec, Yohann Loriot, Guido Kroemer, Aurelien Marabelle, Melodie Bonvalet, Laurence Zitvogel
Summary: Decision making in immuno-oncology plays a crucial role in adapting therapy to the tumor microenvironment. A multiplex functional and dynamic immuno-assay has been developed to predict unresponsiveness to anti-PD-1 mAbs and detect personalized combinatorial regimens in human primary tumors, awaiting validation in prospective clinical trials.
EMBO MOLECULAR MEDICINE
(2021)
Article
Oncology
Ithar Gataa, Laura Mezquita, Caroline Rossoni, Edouard Auclin, Myriam Kossai, Frank Aboubakar, Sylvestre Le Moulec, Julie Masse, Morgane Masson, Nina Radosevic-Robin, Pierre Alemany, Mathieu Rouanne, Virginia Bluthgen, Lizza Hendriks, Caroline Caramella, Anas Gazzah, David Planchard, Jean-Pierre Pignon, Benjamin Besse, Julien Adam
Summary: High-TIL was associated with favorable outcomes in a real-world immunotherapy cohort of patients with NSCLC, but not with chemotherapy, suggesting that TILs may be useful in selecting patients for immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Myriam Kossai, Camelia Radulescu, Julien Adam, Anais Dziegielewski, Nicolas Signolle, Mathilde Sibony, Thierry Lebret, Yves Allory, Mathieu Rouanne
Summary: Plasmacytoid UC differs from conventional UC in pathological features and immune expression, but belongs to the luminal subtype and exhibits an inflamed microenvironment. These findings support the inclusion of plasmacytoid variant of UC in clinical trials evaluating immune checkpoint inhibitors monotherapy or combination immunotherapeutic strategies.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Editorial Material
Oncology
Melodie Bonvalet, Francois-Xavier Danlos, Stephane Champiat, Mathieu Rouanne, Aurelien Marabelle
EUROPEAN JOURNAL OF CANCER
(2022)
Meeting Abstract
Oncology
Mathieu Rouanne, Julien Adam, Camelia Radulescu, Diane Letourneur, Severine Mouraud, Delphine Bredel, Anne-Gaelle Goubet, Tuan Zea Tan, Amelie Bigorgne, Michael Dussiot, Lambros Tselikas, Sandrine Susini, Francois-Xavier Danlos, Roman Chabanon, Nicolas Signolle, Anna Schneider, Sophie Vacher, Ivan Bieche, Thierry Lebret, Yves Allory, Jean-Charles Soria, Jean Paul Thiery, Laurence Zitvogel, Aurelien Marabelle
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Anne-Gaelle Goubet, Leonardo Lordello, Carolina Alves Costa Silva, Isabelle Peguillet, Marianne Gazzano, Maxime Descartes Mbogning-Fonkou, Cassandra Thelemaque, Cedric Lebacle, Constance Thibault, Francois Audenet, Geraldine Pignot, Gwenaelle Gravis, Carole Helissey, Luca Campedel, Morgan Roupret, Evanguelos Xylinas, Idir Ouzaid, Agathe Dubuisson, Marine Mazzenga, Caroline Flament, Pierre Ly, Virginie Marty, Nicolas Signolle, Allan Sauvat, Thomas Sbarrato, Mounia Filahi, Caroline Davin, Gabriel Haddad, Jacques Bou Khalil, Camille Bleriot, Francois-Xavier Danlos, Garett Dunsmore, Kevin Mulder, Aymeric Silvin, Thibault Raoult, Baptiste Archambaud, Shaima Belhechmi, Ivo Gomperts Boneca, Nadege Cayet, Maryse Moya-Nilges, Adeline Mallet, Romain Daillere, Etienne Rouleau, Camelia Radulescu, Yves Allory, Jacques Fieschi, Mathieu Rouanne, Florent Ginhoux, Gwenael Le Teuff, Lisa Derosa, Aurelien Marabelle, Jeroen Van Dorp, Nick Van Dijk, Michiel S. Van der Heijden, Benjamin Besse, Fabrice Andre, Miriam Merad, Guido Kroemer, Jean-Yves Scoazec, Laurence Zitvogel, Yohann Loriot
Summary: CD4+ T cells and PD-L1 expression are correlated with the efficacy of immunotherapy drugs, which is important for the treatment of bladder cancer patients.
Article
Oncology
Marc Hilmi, Natacha Naoun, Alice Boileve, Arthur Geraud, Arnaud Bayle, Arnaud Pages, Marion Aupomerol, Matthieu Rouanne, Francois-Xavier Madec, Fanny Pommeret, Christophe Massard, Capucine Baldini, Florian Scotte, Stephane Champiat
Summary: This prospective study aims to assess supportive care needs, quality of life (QoL), and sexuality in patients enrolled in oncology phase 1 trials. The study found significant supportive care needs in certain subgroups of patients, and identified various factors that impact patients' QoL and sexual function.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Oncology
Laurent Dercle, Samy Ammari, Elvire Roblin, Amelie Bigorgne, Stephane Champiat, Lokmane Taihi, Athena Plaian, Sophie Hans, Sara Lakiss, Lambros Tselikas, Mathieu Rouanne, Eric Deutsch, Lawrence H. Schwartz, Mithat Gonen, Jessica Flynn, Christophe Massard, Jean-Charles Soria, Caroline Robert, Aurelien Marabelle
Summary: Using machine learning algorithms and multivariate analyses, this study found that serum lactate dehydrogenase and liver metastases are key indicators for predicting the survival rate of patients receiving PD-(L)1 immunotherapies. For some patients, PD-(L)1 monotherapies are ineffective, and additional screening methods and treatment approaches are needed.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Francois-Xavier Danlos, Matthieu Texier, Bastien Job, Severine Mouraud, Lydie Cassard, Capucine Baldini, Andrea Varga, Andrey A. Yurchenko, Audrey Rabeau, Stephane Champiat, Diane Letourneur, Delphine Bredel, Sandrine Susini, Yuna Blum, Aurelien Parpaleix, Cedric Parlavecchio, Lambros Tselikas, Jean-Eudes Fahrner, Anne-Gaelle Goubet, Mathieu Rouanne, Saloomeh Rafie, Alae Abbassi, Ines Kasraoui, Marie Breckler, Siham Farhane, Samy Ammari, Salim Laghouati, Anas Gazzah, Ludovic Lacroix, Benjamin Besse, Nathalie Droin, Marc Deloger, Sophie Cotteret, Julien Adam, Laurence Zitvogel, Sergey I. Nikolaev, Nathalie Chaput, Christophe Massard, Jean-Charles Soria, Carlos Gomez-Roca, Gerard Zalcman, David Planchard, Aurelien Marabelle
Summary: Recent research has shown that cancer immunotherapy combinations can improve the overall survival of advanced mesotheliomas, especially for patients who respond to the treatments. This study aimed to understand the biological factors that contribute to the primary resistance of mesotheliomas to immunotherapy and antiangiogenics. The combination of pembrolizumab and nintedanib was tested in thirty patients with advanced malignant pleural mesothelioma, and it was observed that refractory patients recruited cytotoxic T cells in their tumors but had high levels of somatic copy-number alterations and proinflammatory cytokines.
Review
Oncology
Tina B. S. Miholjcic, Heloise Halse, Melodie Bonvalet, Amelie Bigorgne, Mathieu Rouanne, Laurent Dercle, Vishnu Shankar, Aurelien Marabelle
Summary: Immunotherapies have improved cancer patients' survival, but many encounter primary and secondary resistances. Investigating resistance mechanisms to cancer immunotherapies is an active area of research. Recent evidence suggests that elevated levels of LDH may have negative predictive value independent of tumor burden and guide treatment strategies in immuno-oncology. This review explores the potential of LDH-targeted therapeutic strategies to overcome the immunosuppressive effects of LDH and enhance patient survival with cancer immunotherapies.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Rainjade Chung, James McKiernan, Nicholas Arpaia, Aurelien Marabelle, Mathieu Rouanne
Summary: BCG is a live attenuated strain of Mycobacterium bovis, initially developed as a vaccine for tuberculosis. It is the only bacterial therapy approved by the US FDA for clinical use in cancer treatment. BCG is used in patients with high-risk non-muscle invasive bladder cancer, delivered directly into the bladder after tumor resection. Modulating mucosal immunity by exposing the urothelium to BCG has been the main therapeutic approach for this type of cancer.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Antoine Girard, Laurent Dercle, Helena Vila-Reyes, Lawrence H. Schwartz, Astrid Girma, Marc Bertaux, Camelia Radulescu, Thierry Lebret, Olivier Delcroix, Mathieu Rouanne
Summary: By using machine learning, we developed a combination of criteria that accurately identifies pelvic lymph node involvement in bladder cancer patients. The diagnostic performance of this combination is comparable to that of a consensus of experts on [F-18]FDG PET/CT scans.
EUROPEAN RADIOLOGY
(2023)
Article
Medicine, Research & Experimental
Mathieu Rouanne, Julien Adam, Camelia Radulescu, Diane Letourneur, Delphine Bredel, Severine Mouraud, Anne-Gaelle Goubet, Marion Leduc, Noah Chen, Tuan Zea Tan, Nicolas Signolle, Amelie Bigorgne, Michael Dussiot, Lambros Tselikas, Sandrine Susini, Francois-Xavier Danlos, Anna K. Schneider, Roman Chabanon, Sophie Vacher, Ivan Bieche, Thierry Lebret, Yves Allory, Jean-Charles Soria, Nicholas Arpaia, Guido Kroefinet, Oliver Kepp, Jean Paul Thiery, Laurence Zitvogel, Aurelien Marabelle
Summary: In patients with high-risk, nonmuscle-invasive bladder cancer (NMIBC), two distinct patterns of immune subversion upon BCG relapse have been identified, which can predict the prognosis of the patients.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
